Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1120398 | 0.85 | EPHX1 (0.39) | THRBLMNAHTR2AHRH1EPHX1 | |
| SCHEMBL9958207 | 0.81 | THRB (0.38) | THRBLMNAEPHX1 | |
| SCHEMBL12283218 | 0.77 | — | — | |
| SCHEMBL15579722 | 0.77 | THRB (0.35) | THRBLMNA | |
| SCHEMBL10639327 | 0.77 | THRB (0.35) | THRBLMNA | |
| SCHEMBL13185663 | 0.77 | CYP2C19 (0.38) | THRBLMNA | |
| SCHEMBL5666168 | 0.76 | THRB (0.50) | THRBLMNA | |
| SCHEMBL14241232 | 0.75 | LMNA (0.38) | THRBLMNA | |
| SCHEMBL23223707 | 0.75 | EPHX1 (0.34) | HTR2AHRH1EPHX1 | |
| SCHEMBL13167557 | 0.73 | THRB (0.32) | THRBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116251226-B | Radiopaque development embolism microsphere and preparation method thereof | 科睿驰（深圳）医疗科技发展有限公司 | 2025-04-08 | — | — | CN | disclosed |
| US-11787803-B2 | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| CN-116251226-A | Radiopaque development embolism microsphere and preparation method thereof | 科睿驰（深圳）医疗科技发展有限公司 | 2023-06-13 | — | — | CN | disclosed |
| US-20220169647-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
| US-11292791-B2 | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| US-20200216445-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS, INC. | 2020-07-09 | — | — | US | disclosed |
| EP-3303333-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2019-11-20 | — | — | EP | disclosed |
| US-20180074015-A1 | Fluorescent pI Markers for Isoelectric Focusing Separations and Fluorescent Labeling | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2018-03-15 | — | — | US | disclosed |
| WO-2018011090-A1 | HYDROXYQUINOLINONE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-18 | — | — | WO | disclosed |
| US-9689841-B2 | Fluorescent pI markers for isoelectric focusing separations and fluorescent labeling | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2017-06-27 | — | — | US | disclosed |
| WO-2012017030-A1 | COMPOUNDS WITH ANTIBACTERIAL ACTIVITY AGAINST CLOSTRIDIUM | ELANCO ANIMAL HEALTH IRELAND LIMITED (IE) | 2012-02-09 | — | — | WO | disclosed |
| EP-2374802-A1 | KYNURENINE PRODUCTION INHIBITOR | Kyowa Hakko Kirin Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20110237584-A1 | KYNURENINE PRODUCTION INHIBITOR | KYOWA KIRIN CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| US-20100305033-A1 | HYDROXYALKYL STARCH DERIVATIVES AND PROCESS FOR THEIR PREPARATION | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305033-A1 | HYDROXYALKYL STARCH DERIVATIVES AND PROCESS FOR THEIR PREPARATION | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2010-12-02 | — | — | US | disclosed |
| WO-2010053182-A1 | KYNURENINE PRODUCTION INHIBITOR | 協和発酵キリン株式会社 (JP) | 2010-05-14 | — | — | WO | disclosed |
| WO-2009077154-A1 | HYDROXYALKYL STARCH DERIVATIVES AND PROCESS FOR THEIR PREPARATION | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2009-06-25 | — | — | WO | disclosed |
| EP-0122761-B1 | HERBICIDAL TETRAHYDROBENZOTHIAZOLE DERIVATIVES | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1990-08-29 | — | — | EP | disclosed |
| US-4561877-A | Derivatives of tetrahydrobenzothiazole and herbicidal compositions containing the same as active ingredient | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1985-12-31 | — | — | US | disclosed |
| EP-0122761-A2 | Herbicidal tetrahydrobenzothiazole derivatives | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1984-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216445-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | EP300, CREBBP, BRD3 | THRB 1694/4885LMNA 1168/4885HTR2A 3209/4885 |
| US-11292791-B2 | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors | EP300, CREBBP, BRD3 | THRB 1694/4885LMNA 1168/4885HTR2A 3209/4885 |
| US-20180074015-A1 | Fluorescent pI Markers for Isoelectric Focusing Separations and Fluorescent Labeling | PDAP1, PAIP1, IK | THRB 4505/4885LMNA 1434/4885HTR2A 4712/4885 |
| US-20220169647-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | EP300, CREBBP, BRD3 | THRB 1694/4885LMNA 1168/4885HTR2A 3209/4885 |
| US-20110237584-A1 | KYNURENINE PRODUCTION INHIBITOR | KYNU, KMO, IDO1 | THRB 1433/4885LMNA 4183/4885HTR2A 199/4885 |
| US-11787803-B2 | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors | EP300, CREBBP, BRD3 | THRB 1694/4885LMNA 1168/4885HTR2A 3209/4885 |
| US-20100305033-A1 | HYDROXYALKYL STARCH DERIVATIVES AND PROCESS FOR THEIR PREPARATION | HDHD5, KHK, SORD | THRB 4854/4885LMNA 1787/4885HTR2A 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.